Prosecution Insights
Last updated: November 18, 2026

Novo Biotech Corp.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Novo Biotech Corp. is currently active in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 2 pending office actions, which are distributed across 2 distinct examiners. This arrangement indicates that the company's current prosecution efforts are spread across multiple individuals, requiring a strategy that accounts for different examiner perspectives. The involvement of 2 distinct art units further suggests that the technical subject matter is being reviewed by various specialized groups within the patent office.

The busiest examiner for this portfolio is FOLEY, SHANON A, who is responsible for 1 busiest_examiner_pending office action. Because this examiner only manages a portion of the total pending workload, the applicant must maintain separate dialogues with each of the examiners involved. This lack of concentration means that the outcomes in one case may not necessarily influence the progression of others in the biotechnology and pharmaceutical sector.

Practitioners should observe that the 2 pending office actions are handled by an equal number of examiners and art units. This structure prevents a single examiner from becoming a bottleneck for the entire portfolio. However, it also requires the applicant to tailor their arguments to the specific requirements of FOLEY, SHANON A and the other officials overseeing the 1 pending action assigned to them.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
2
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FOLEY, SHANON A 1 73.2% +18.2%
QIAN, CELINE X 1 47.5% +17.4%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18005367 Subunit Vaccine Composition For African Swine Fever, And Preparation Therefor And Use Thereof FOLEY, SHANON A —
18095016 Recombinant Pseudorabies Virus and Vaccine Composition thereof QIAN, CELINE X —

Top Art Units

Art UnitApps
1671 1
1637 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18005367 Subunit Vaccine Composition For African Swine Fever, And Preparation Therefor And Use Thereof FOLEY, SHANON A 1671 §112 Non-Final OA — Pending Jan 13, 2023
18095016 Recombinant Pseudorabies Virus and Vaccine Composition thereof QIAN, CELINE X 1637 §112 Final Rejection — Pending Jan 10, 2023

Managing Novo Biotech Corp.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Novo Biotech Corp. have?

Novo Biotech Corp. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Novo Biotech Corp. applications?

Shanon A Foley has the most, with 1 of Novo Biotech Corp.'s pending office actions.

What technology area are Novo Biotech Corp.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month